

1 **Multi-site validation of a functional assay to adjudicate SCN5A Brugada**
2 **Syndrome-associated variants**

3 Joanne G. Ma,^{1,2#} Matthew J. O'Neill,^{3#} Ebony Richardson,⁴ Kate L. Thomson,⁵ Jodie Ingles,⁴
4 Ayesha Muhammad,³ Joseph F. Solus,⁶ Giovanni Davogustto,⁷ Katherine C. Anderson,⁷ M.
5 Benjamin Shoemaker,⁷ Andrew B. Stergachis,⁸ Brendan J. Floyd,⁹ Kyla Dunn,⁹ Victoria N.
6 Parikh,⁹ Henry Chubb,⁹ Mark J. Perrin,¹⁰ Dan M. Roden,¹¹ Jamie I. Vandenberg,^{1,2*} Chai-Ann
7 Ng,^{1,2*} Andrew M. Glazer,^{6*}

8

9 # Equally contributed to this work

10 * Jointly supervised this work

11

12 1. Mark Cowley Lidwill Research Program in Cardiac Electrophysiology, Victor Chang
13 Cardiac Research Institute, Darlinghurst, NSW, Australia.

14 2. School of Clinical Medicine, UNSW Sydney, Darlinghurst, NSW, Australia.

15 3. Vanderbilt University School of Medicine, Nashville, TN, USA.

16 4. Clinical Genomics Laboratory, Centre for Population Genomics, Garvan Institute of
17 Medical Research, Darlinghurst, NSW, Australia and Murdoch Children Research Institute,
18 Melbourne, Australia.

19 5. Oxford Genetics Laboratories, Churchill Hospital, Oxford, UK.

20 6. Vanderbilt Center for Arrhythmia Research and Therapeutics (VanCART), Division of
21 Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center,
22 Nashville, TN, USA.

23 7. Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University
24 Medical Center, Nashville, TN, USA.

25 8. University of Washington School of Medicine, Department of Medicine, Seattle, WA, USA.

26 9. Stanford Center for Inherited Cardiovascular Disease, Stanford University School of
27 Medicine, Stanford, CA, USA.

28 10. Department of Genomic Medicine, Royal Melbourne Hospital, Victoria, Australia.

29 11. Vanderbilt Center for Arrhythmia Research and Therapeutics (VanCART), Departments
30 of Medicine, Pharmacology, and Biomedical Informatics, Vanderbilt University Medical
31 Center, Nashville, TN, USA.

32

33 *Correspondence: j.vandenberg@victorchang.edu.au (J.I.V.), c.ng@victorchang.edu.au
34 (C.N), andrew.m.glazer@vumc.org (A.M.G.)

35

36 **Abstract**

37 Brugada Syndrome (BrS) is an inheritable arrhythmia condition that is associated with rare,
38 loss-of-function variants in the cardiac sodium channel gene, *SCN5A*. Interpreting the
39 pathogenicity of *SCN5A* missense variants is challenging and ~79% of *SCN5A* missense
40 variants in ClinVar are currently classified as Variants of Uncertain Significance (VUS). An *in*
41 *vitro* *SCN5A*-BrS automated patch clamp assay was generated for high-throughput
42 functional studies of Na_v1.5. The assay was independently studied at two separate research
43 sites – Vanderbilt University Medical Center and Victor Chang Cardiac Research Institute –
44 revealing strong correlations, including peak *I*_{Na} density ($R^2=0.86$). The assay was calibrated
45 according to ClinGen Sequence Variant Interpretation recommendations using high-
46 confidence variant controls (n=49). Normal and abnormal ranges of function were

47 established based on the distribution of benign variant assay results. The assay accurately
48 distinguished benign controls (24/25) from pathogenic controls (23/24). Odds of
49 Pathogenicity values derived from the experimental results yielded 0.042 for normal function
50 (BS3 criterion) and 24.0 for abnormal function (PS3 criterion), resulting in up to strong
51 evidence for both ACMG criteria. The calibrated assay was then used to study *SCN5A* VUS
52 observed in four families with BrS and other arrhythmia phenotypes associated with *SCN5A*
53 loss-of-function. The assay revealed loss-of-function for three of four variants, enabling
54 reclassification to likely pathogenic. This validated APC assay provides clinical-grade
55 functional evidence for the reclassification of current VUS and will aid future *SCN5A*-BrS
56 variant classification.

57

58

59 **Introduction**

60 Brugada Syndrome (BrS) is an autosomal dominant disease characterized by ST-segment
61 elevation in the right precordial leads (V1-V3) of the electrocardiogram (ECG).¹ Patients with
62 the definitive (“Type 1”) BrS ECG pattern are at increased risk of sudden cardiac death due
63 to ventricular fibrillation.² Sudden cardiac death may be the first disease manifestation,
64 making early identification of at-risk patients critical. Up to 30% of BrS patients have rare
65 variants in *SCN5A*, which encodes $Na_v1.5$, the cardiac voltage-gated sodium channel.³ BrS-
66 associated *SCN5A* variants are loss-of-function (LOF) and decrease cardiac excitability and
67 reduce electrical conduction velocity. A ClinGen expert panel asserted that *SCN5A* is the
68 only gene for which rare variants are definitively associated with BrS.⁴ BrS is also
69 substantially influenced by common genetic variation, with 12 common loci identified
70 throughout the genome in a recent genome-wide association study.⁵

71 Genetic testing offers the ability to identify individuals at risk for BrS, and proactively
72 optimize medical management before they experience life-threatening cardiac events.^{6,7}
73 However, classification of variants in *SCN5A* remains challenging as *SCN5A* variants can
74 have normal function or cause LOF or gain-of-function (GOF). All variants are currently
75 classified by the ACMG/AMP v3 framework as benign (B), likely benign (LB), variant of
76 uncertain significance (VUS), likely pathogenic (LP), or pathogenic (P).⁸ Unfortunately, ~79%
77 of missense *SCN5A* variants in ClinVar are currently classified as VUS,^{9,10} This high burden
78 of VUS has resulted in underdiagnosis, misdiagnosis, or inappropriate interventions.^{11,12}

79 High-throughput functional assays provide an opportunity to improve variant classifications.⁸
80 Manual patch clamping is the gold-standard method for measuring the function of ion
81 channel variants. However, patch clamping is low-throughput, and individual reports usually
82 describe functional characteristics for one or a small number of variants compared to wild-
83 type, precluding assay calibration and generalization across laboratories. High-throughput
84 automated patch-clamp (APC) electrophysiology platforms enable the rapid functional
85 assessment of large numbers of ion channel variants.¹³⁻¹⁷ In the 2015 v3 ACMG/AMP
86 guidelines, well-established functional assay results were applied at a strong level.⁸ These
87 criteria are termed BS3 for a normal assay result or PS3 for an abnormal assay result. In
88 2020, the ClinGen Sequence Variant Interpretation (SVI) Working Group recommended
89 instead applying the ACMG/AMP functional assay criteria at a range of evidence strengths
90 depending on the assay's performance on pathogenic and benign variant controls.¹⁸ Jiang et
91 al.¹⁶ previously deployed this framework on a APC assay for *KCNH2*-related Long QT
92 Syndrome, with functional data initially providing moderate-strength evidence for clinical
93 classifications.¹⁶ This *KCNH2* assay was recently upgraded to strong evidence strength by
94 including more variant controls.¹⁹ This framework has not yet been applied to any other APC
95 assays, such as an APC assay for Brugada Syndrome (*SCN5A*-BrS). Furthermore, multi-site
96 replication of APC assay calibration has not yet been reported, an important step in
97 promoting reproducibility.

98 In this study, we calibrate an *SCN5A*-BrS APC assay using a large set of P/LP and B variant
99 controls. We demonstrate high replicability of this assay between two independent research
100 centers and high concordance with clinical classifications. We then used the calibrated
101 assay to provide functional evidence for reclassification of *SCN5A* VUS identified in clinical
102 cases of BrS and other severe arrhythmias.

103

104

105 **Materials and Methods**

106 ***SCN5A* transcript**

107 Variants were annotated and experimentally studied using the MANE Select *SCN5A*
108 transcript ENST00000423572.7 (NM_000335.5), the most common transcript in the adult
109 heart.²⁰ This 2015-amino acid transcript includes the adult exon 6A and does not include the
110 alternatively spliced Gln1077 residue. In some previous studies, variants have been
111 annotated according to the 2016-amino acid transcript that includes adult exon 6A and
112 contains Gln1077, ENST00000333535.^{17,21} Table S1 shows variants annotated according to
113 both reference transcripts.

114

115 **Classification of *SCN5A* variants**

116 Variant controls were classified using the 2015 ACMG/AMP v3 criteria for variant
117 interpretation⁸ by a team of clinical geneticists and cardiac genetic counselors. Candidate
118 *SCN5A* variants were selected from the ClinVar⁹ and gnomAD variant databases (v2.1.1 and
119 v3.1.2).²² For the classification of benign variants, the maximum credible allele frequency of
120 *SCN5A* variants in population databases was defined using the allele frequency app
121 (<http://cardiodb.org/allelefrequencyapp/>)²³ with an inputted BrS prevalence of 1 in 2000,²⁴

122 allele heterogeneity of 0.02, genetic heterogeneity of 0.3, and penetrance set to the lowest
123 setting of 0.01. Using these thresholds, BA1 can be applied as the stand-alone criteria for all
124 variants meeting a maximum credible population allele frequency of 0.00015.²⁵ However, for
125 identifying control benign variants, we conservatively applied BA1 to variants with a
126 maximum credible allele frequency of 0.0003 in gnomAD. P/LP variants for BrS were
127 classified with multiple ACMG/AMP criteria,²⁶ including the number of probands with
128 consistent disease phenotype (PS4), absence or rarity of allele in large scale population
129 databases (maximum allele frequency of 3 in 100,000 alleles; PM2_supporting), location of
130 variant (PM1),²⁷ *in silico* predictors (PP3) including Metascores (MetaLR, MetaSVM,
131 MetaRNN, REVEL²⁸) and VarSome²⁹, and segregation data (PP1). Clinical databases from
132 the Centre for Population Genomics and Oxford Genetics Laboratories provided additional
133 proband evidence for pathogenic classifications. The final set of 25 B variant controls is
134 shown in Table S2 and the final set of 24 P/LP variant controls is shown in Table S3.

135

136 **SCN5A automated patch clamp assay**

137 We followed previously reported protocols to independently generate stable HEK293 variant
138 cell lines (Victor Chang Cardiac Research Institute, VCCRI;^{16,30} Vanderbilt University Medical
139 Center, VUMC).^{17,31} Briefly, *SCN5A* variant constructs were cloned or subcloned
140 independently using a QuikChange Lightning Mutagenesis kit (Agilent) into a
141 AttB:SCN5A:IRES:mCherry-blasticidinR plasmid (VUMC), or into pcDNATM5/FRT/TO
142 (Thermo Fisher Scientific) by Genscript Inc. (Piscataway, USA) (VCCRI). See Table S4 for a
143 description of all primers used in this study. Plasmids encoding different variants were
144 transfected into modified HEK293 cell lines at each site. VUMC used a “negative selection”
145 landing pad system (a gift from Kenneth Matreyek and Doug Fowler).³² HEK293 negative
146 selection landing pad cells were co-transfected with a AttB-containing *SCN5A* variant
147 plasmid and a plasmid bearing Bxb1 recombinase (a gift from Pawel Pelczar³³, Addgene
148 plasmid #51271) with Lipofectamine 2000 (Thermo Fisher Scientific) following

149 manufacturer's instructions. Cells were grown in selection media containing 5 ug/mL
150 doxycycline (to induce promoter expression; Sigma-Aldrich), 100 ug/mL blasticidin S (to
151 eliminate cells not expressing the blasticidin-resistant plasmid; Sigma-Aldrich), and 10 nM
152 AP1903 (to eliminate non-integrated cells expressing a AP1903-inducible caspase gene;
153 MedChemExpress). Cells were grown for 10 days and screened by flow cytometry to confirm
154 expression levels. VCCRI generated stable cell lines by co-transfecting an *SCN5A* variant-
155 expressing pcDNATM5/FRT/TO plasmid with a pOG44 Flp-Recombinase Expression Vector
156 (Thermo Fisher Scientific). The plasmids were transfected with Lipofectamine 3000 (Thermo
157 Fisher Scientific) following manufacturer's instructions. Cell lines were grown in selection
158 media containing 200 ug/mL of Hygromycin (Thermo Fisher Scientific) and 10 ug/mL
159 Blasticidin (InvivoGen) for up to 14 days, and *SCN5A* expression was induced with 200
160 ng/mL doxycycline (Sigma-Aldrich) 48 hours prior to experimentation. Electrophysiology
161 experiments at both sites were conducted on the SyncroPatch 384 PE (Nanion
162 Technologies, Munich, Germany) using Nanion chips containing *SCN5A* wild-type (WT) and
163 variant control cell lines. Data analysis was performed using site-specific, custom *SCN5A*
164 analysis scripts in R (VUMC) and Matlab (VCCRI). See Figure 1 for an overview of the
165 methods used in this project. See Supplemental Methods and Figure S1 for detailed
166 electrophysiology protocols and site-specific methods.

167

168 **Quality control, sample size, and reproducibility**

169 Both sites implemented common quality control criteria for seal resistance (R_{seal}),
170 capacitance (C_{slow}), series resistance (R_{series}) and residual background current after leak
171 correction. We also performed QC for time to peak as a surrogate for adequate voltage-
172 clamp control. Lastly, current amplitude thresholds were applied during analysis of channel
173 gating parameters: steady state activation (SSA), steady state inactivation (SSI), and

174 recovery from inactivation (RFI). Specific QC parameters applied at each site are presented
175 in Supplemental Methods.

176 Power calculations for sample sizes were performed based on cells expressing WT *SCN5A*
177 that passed QC controls. Sample size calculation was performed (see Supplemental
178 Methods) to detect a 25% difference at 90% power, where $\alpha = 0.05$. Tests of normality were
179 implemented with Shapiro-Wilk tests. Non-normal variables were transformed with a square
180 root-transformation, then normalized to the WT mean or individual chips or groups of chips
181 to control for plate-to-plate and batch-to-batch variation, respectively.

182

183 **Z-score and OddsPath calculations**

184 For each functional property, normalized means of WT and benign variants were combined
185 to establish thresholds to distinguish variants with normal function from variants with
186 abnormal function. Z-scores were calculated (Equation 1) for all measured values to quantify
187 each variant's function, with smaller Z-scores associated with lower values (such as lower
188 current density).

$$189 \quad Z = \frac{\text{Raw value} - \text{Mean}_{\text{Benign}}}{SD_{\text{Benign}}} \quad \text{Equation 1}$$

190 For I_{Na} density, variants with Z-scores between -2 and +2 were considered to have normal
191 function. For I_{Na} density, variants with a Z-score between -2 and -4 were considered
192 moderate LOF and variants with a Z-score below -4 were considered severe LOF¹⁹. For
193 SSA, SSI, and RFI, variants with $Z > 4$ or $Z < -4$ were considered abnormal. The evidence
194 strength for each *SCN5A* functional property was calculated according to the Odds of
195 Pathogenicity (OddsPath) equations as recommended by the ClinGen Sequence Variant
196 Interpretation working group^{18,26}. A spreadsheet detailing the OddsPath calculations is
197 presented in Table S8.

198

199 **Analysis of channel functional properties**

200 *SCN5A* functional properties analyzed in this assay were peak sodium current (I_{Na}) density,
201 SSA, SSI and RFI. Diagrams of voltage protocols are presented in Figure S1 and equations
202 for analysis used in this study are presented in the Supplementary Methods. The I_{Na} density
203 was measured at -30 mV following a holding potential of either -120 mV (VUMC and VCCRI)
204 or -90 mV (VCCRI). After quality control, activating current amplitude was divided by cell
205 capacitance to calculate current density normalized to cell size, measured in pA/pF. SSA
206 was obtained by measuring currents in cells depolarized from a holding potential of -120 mV
207 to voltages in the range -100 mV to 0 mV, at 5 mV increments. SSA was fit to the Boltzmann
208 equation using nonlinear least-squares to determine the voltage at which half of the
209 channels were activated (SSA V_{50}). SSI was determined after holding channels at voltages
210 in the range -140 mV to -40 mV for 500 ms (in 5 mV increments) then measuring tail current
211 amplitudes recorded at -30 mV. These values were fit to the Boltzmann equation to
212 determine SSI V_{50} . RFI was determined by the ratio of current amplitude at a test pulse to
213 current amplitude at a pre-pulse with increasing time intervals between the two pulses. The
214 time at which channels were half recovered (T_{50}) was used for analysis.

215

216 **Clinical evaluation and genetic testing**

217 *SCN5A* VUS were identified in patients with BrS diagnoses or severe cardiac conduction
218 disease from four tertiary care centers: Vanderbilt University Medical Center, Stanford
219 Medicine, University of Washington Hospital, and The Royal Melbourne Hospital. All studies
220 were approved by local Institutional Review Boards/Research Ethics Committees and
221 informed consent was obtained as required by these entities. Clinical information was
222 obtained through retrospective review of medical records. Patients underwent commercial

223 genetic testing using gene-panels. Functional characterization of each clinical *SCN5A* VUS
224 using the calibrated assay was performed as described above. Although the APC OddsPath
225 calculations supported the use of BS3_strong, we conservatively applied a graded evidence
226 strength scheme. Z-scores of the square root transformed current density values were used
227 to calculate the appropriate ACMG criterion (PS3_strong for $Z < -4$, PS3_moderate for $-4 < Z$
228 < -3 , PS3_supporting for $-3 < Z < -2$, BS3_supporting for $-2 < Z < -1$, and BS3_moderate for
229 $Z > -1$). We note that we conservatively applied BS3_moderate evidence strength for
230 variants with $-1 < Z < 1$ and BS3_supporting for $-2 < Z < -1$ and $Z > 1$. This was due to
231 caution over misclassifying a disease-causing variant as benign or likely benign, and
232 because we have not yet calibrated the assay to detect other types of *SCN5A* dysfunction
233 such as GOF. Variant reclassification was independently performed at each clinical site by a
234 genetic counselor, clinical geneticist, or physician specializing in genomic medicine.

235

236

237 **Results**

238 **Square root transformation, power calculation**

239 We measured typical I_{Na} currents from 2,727 cells expressing WT *SCN5A* (Figure 2A-B).
240 The raw current densities showed a non-Gaussian distribution (Figure 2C-D, $p < 0.0001$,
241 Shapiro-Wilk test). The current density values were converted to a more normal distribution
242 by application of a square-root transformation (Figure 2E-F; $p = 0.304$ and $p < 0.0001$ at
243 VCCRI and VUMC, respectively; Shapiro-Wilk test).^{16,34} Using a sample size power
244 calculation (see Supplemental Equations), we determined that a minimum of 30 cells per
245 variant was required to detect a 25% difference in current density at 90% power with a 95%
246 confidence interval. We therefore measured at least 30 cells per site for each variant with
247 replicates spanning independent transfections, chips, and experimental days.

248

249 **Peak I_{Na} density distinguishes benign from pathogenic variants**

250 Many BrS-associated *SCN5A* variants have reductions in peak I_{Na} density, the maximum
251 amount of current through the channel.²¹ Z-scores were calculated using the distribution of
252 25 benign variant controls as reference. Z-scores between -2 and 2 were considered normal,
253 and Z-scores between -2 and -4 were considered moderate LOF, and Z-scores smaller than
254 -4 were considered severe LOF. Normalized current densities for B and P/LP variant
255 controls are shown for VCCRI (Figure 3A) and VUMC (Figure 3B), and the combined VCCRI
256 and VUMC dataset (Figure 3C). Variant-level data are summarized in Tables S5-S7. Across
257 the 49 variants, we observed excellent correlation between sites for peak I_{Na} density despite
258 slight differences in cell systems, protocols, and analysis pipelines (Figure 3D; $R^2 = 0.86$).
259 Overall, 25/25 B and 23/24 P/LP variant controls had matching results between the two sites
260 for peak I_{Na} density, considering this variable as a binary outcome of normal or abnormal.
261 The only variant discordant between the two sites was p.Arg1631His, an LP variant that had
262 reduced I_{Na} density in the VCCRI dataset and normal function in the VUMC dataset (Figure
263 3).

264 We observed a strong predictive ability of peak I_{Na} current to distinguish benign from
265 pathogenic variant controls. In the merged dataset (Figure 3C), 22 of 24 P/LP variant
266 controls had moderate or severe LOF ($Z < -2$). Two P/LP variant controls had current density
267 within normal ranges: p.Arg1643Cys ($Z = -0.71$) and p.Arg1631His ($Z = -1.6$), though VCCRI
268 observed partial LOF for p.Arg1631His (Figure 3A). As we describe below, both sites
269 measured abnormal gating properties for p.Arg1631His. In the merged dataset (Figure 3C),
270 24 of 25 B variant controls were within the normal range of function ($Z > -2$). One benign
271 variant, p.Ser216Leu, had moderate LOF at both sites and a final Z-score of -3.39. Overall,
272 peak I_{Na} density was concordant with ACMG/AMP classifications for 46/49 variants (93.9%).

273

274 **Incorporation of additional channel gating parameters**

275 We next studied variant effects on three additional channel gating parameters: steady state
276 activation (SSA), steady-state inactivation (SSI), and recovery from inactivation (RFI) (Figure
277 4, Supplementary Table 5-7). These parameters quantify the voltages at which channels
278 activate and inactivate and the time needed to recover from inactivation. We observed good
279 to excellent correlation between VCCRI and VUMC for these parameters (SSA $R^2=0.44$; SSI
280 $R^2=0.48$; RFI T_{50} $R^2=0.91$; Figure S2-4). Unlike peak I_{Na} density (Figure 3), none of the three
281 gating parameters strongly distinguished B from P/LP controls (Figure 4). We also note that
282 for most variants with LOF – including most P/LP variant controls – these gating parameters
283 could not be measured due to the small I_{Na} . Therefore, we applied a more conservative Z-
284 score threshold of ± 4 for altered effects. Using this cutoff, five P/LP variants (p.Glu1224Lys,
285 p.Ala735Val, p.Glu1783Lys, p.Arg1631His, and p.Arg1631Cys) and no B variants showed
286 altered gating parameters (Table 1, Figure 4). In particular, two variants had extreme
287 changes in RFI ΔT_{50} : p.Arg1631Cys ($Z = 72.74$) and p.Arg1631His ($Z = 106.09$; Figure 4E-F,
288 H-I, Table 1). This finding resolves the initial discordance between the LP classification for
289 p.Arg1631His and the normal-range peak I_{Na} density measured at VUMC. Thus, an
290 integrated analysis of peak current density and other gating parameters yields 23/24 B and
291 24/25 P/LP variants that have concordant functional assay results and clinical classifications.
292

293 **Peak I_{Na} density for depolarization from a -90 mV holding potential**

294 Peak I_{Na} density is commonly measured from a holding potential of -120 mV, which ensures
295 that nearly all channels begin the measurement from the closed state. However, under
296 physiological conditions, the resting cardiomyocyte membrane potential is closer to -90
297 mV.³⁵ We hypothesized that variants with abnormal gating properties such as hyperpolarized
298 SSI may have reduced current density when measured from a holding potential of -90mV
299 (Figure 5A). To test this hypothesis, at VCCRI, peak I_{Na} densities were measured from a

300 holding potential of -90 mV (Figure 5). Peak I_{Na} densities measured from holding potentials
301 of -90 mV and -120 mV were highly correlated ($R^2=0.95$, Figure 5B). However, three variants
302 (p.Arg1631Cys, p.Arg1631His and p.Glu1783Lys) had lower I_{Na} density when measured
303 from a holding potential of -90 mV compared to -120 mV (Figure 5B). All three of these
304 variants also had hyperpolarized SSI (Figure 4D, Table 1). We next performed square root
305 transformations of the -90 mV peak I_{Na} density measurements, and used the mean and
306 standard deviation of benign variant controls to define Z-scores. This single parameter (peak
307 I_{Na} density measured from a holding potential of -90 mV) yielded 25/25 B and 23/24 P/LP
308 variant controls that have concordant functional assay results and clinical classifications
309 (Figure 5C). In particular, the measurement at -90 mV peak improved the concordance of
310 the B variant p.Ser216Leu ($Z = -3.39$ at a holding potential of -120 mV, $Z = -1.72$ at -90 mV)
311 whilst also increasing the B variant p.Glu446Lys ($Z = 1.65$ at a holding potential of -120 mV,
312 $Z = 2.37$ at -90 mV). Evaluation of p.Glu446Lys gating parameters measured in this study
313 does not suggest altered function (Table S5-7) . However, as this SCN5A-BrS assay is only
314 validated against LOF, a calibrated GOF assay may be valuable to explore this variant
315 further.

316

317 **Establishment of evidence strength for functional data**

318 Recommendations by the ClinGen SVI working group¹⁸ were applied to evaluate the
319 strength of our two SCN5A-BrS assay implementations (Figure 6; Table S8). For our first
320 implementation which combined -120 mV holding potential measurements and gating
321 properties, we observed 24/25 concordant B variants and 23/24 concordant P/LP variants
322 (Figure 6A). This yielded OddsPath scores of 24.0 for pathogenic evidence, and 0.043 for
323 benign evidence (Figure 6B). For our second implementation which considered the single
324 parameter of peak I_{Na} density from a holding potential of -90 mV, we observed 25/25
325 concordant B variants and 23/24 concordant P/LP variants. (Figure 6C). This yielded

326 OddsPath scores of 24.0 for pathogenic evidence, and 0.042 for benign evidence. (Figure
327 6D). In both cases, these values correspond to application of up to PS3_strong (abnormal
328 function) and BS3_strong (normal function) criteria in the ACMG/AMP classification
329 scheme.⁸

330

331 **Functional investigation of clinical SCN5A VUS**

332 The calibrated APC assay was used to assess the function of SCN5A VUS identified in
333 patients with a clinical diagnosis of BrS or other severe arrhythmia phenotypes associated
334 with SCN5A LOF variants.³⁶ A list of genes tested for each proband is available in Table S9,
335 additional detected non-SCN5A variants are available in Table S10, and classification
336 criteria are available in Table S11. Limited pedigrees with clinical annotations are shown in
337 Figure 7, with the sexes of family members anonymized.

338 *Family 1.* The proband was resuscitated from a ventricular fibrillation cardiac arrest during
339 their teenage years. Cardiac workup led to a diagnosis of Brugada Syndrome and
340 Progressive Cardiac Conduction Defect. Genetic testing identified an in-frame insertion in
341 SCN5A, p.Asn1378_Lys1379insValPhe (c.4133_4134insTGTGTT), which was classified as
342 VUS. APC revealed that the variant was LOF ($Z = -7.62$), enabling reclassification to LP after
343 application of PS3_strong (Figure 7). Cascade screening revealed that the SCN5A variant
344 was inherited. The proband's affected parent had a history of a seizure disorder and was
345 subsequently found to have cardiac conduction disease. The parent with the SCN5A variant
346 had a history of a seizure disorder and was subsequently found to have cardiac conduction
347 disease. Additionally, two of the probands' grandparents (one on each side of the family) had
348 died suddenly in their 30s or 40s.

349 *Family 2.* The proband was a woman in her 40s who presented after an episode of syncope.
350 Workup revealed fever-induced Type 1 (*i.e.*, definite) Brugada ECG pattern. Genetic testing
351 uncovered the in-frame deletion p.Phe1751del (c.5251_5253del), which was classified as

352 VUS. APC revealed that the variant was LOF ($Z = -7.44$), enabling reclassification to likely
353 pathogenic after application of PS3_strong. The proband had a family history of recurrent
354 syncope, seizures, and one cardiac arrest. However, besides the proband, the family was
355 hesitant to undergo genetic evaluation, precluding segregation analysis.

356 *Family 3.* The proband developed complete heart block at a young age and had a 13 second
357 pause, and received an implanted cardioverter defibrillator (ICD). He developed ventricular
358 tachycardia, received shocks from his ICD, and developed heart failure as an adult. Genetic
359 testing identified an *SCN5A* VUS p.Asn932Lys (c.2796T>G). APC revealed that the variant
360 was LOF ($Z = -6.52$), enabling reclassification to LP after application of PS3_strong.
361 Cascade screening identified the proband's two young children as variant carriers, and both
362 had a prolonged PR interval (202 msec and 172 msec).

363 *Family 4.* The proband was a woman in her 60s with an incidental finding of BrS Type 1
364 ECG and rate-related left bundle branch block during exercise testing. She had no history of
365 syncope and there was no family history of sudden cardiac death. Genetic testing identified
366 an *SCN5A* variant p.Arg1305Cys (c.3913C>T), which has an allele count of 12 in gnomAD
367 v4, and was classified as a VUS. Using APC, we assessed the variant to have normal
368 function ($Z = -0.33$) and concluded that in this case the *SCN5A* variant was likely not the
369 cause of the BrS ECG pattern. This variant remained classified as VUS by the clinical testing
370 laboratory after incorporation of the functional data (BS3_moderate).

371

372 *Reanalysis of previously published APC data*

373 Lastly, we reanalyzed all previously published *SCN5A* APC assay results from our
374 group^{17,31,37} (Table S12). This reanalysis used the same analysis protocol described in this
375 paper, including features like square root transformation of current densities and Z-score-
376 derived cutoffs that were not implemented in our previous studies. We also assigned

377 recommended functional evidence BS3/PS3 strengths to these variants using our updated
378 analysis framework (Table S12).

379

380

381 **Discussion**

382 This study describes an *SCN5A* functional assay that was independently tested and
383 calibrated by two research centers to facilitate *SCN5A*-BrS variant classification. Significant
384 benefits of this assay include replicability across sites, the ability to distinguish B and P/LP
385 variant controls following ClinGen guidelines, and implementation of Z-scores to
386 quantitatively interpret VUS. We also demonstrate a single parameter (peak current
387 measured from a physiological holding potential of -90 mV) that can accurately distinguish B
388 from P/LP controls.

389

390 **Multi-site validation of a *SCN5A*-BrS patch-clamp assay**

391 Independent data generation and analyses were performed at two independent sites with
392 similar experimental and analysis pipelines. To determine the reproducibility of the *SCN5A*
393 APC assay, each site independently tested all variant controls. Between the two sites, we
394 observed strong correlations for peak current density ($R^2 = 0.86$) and good to excellent
395 correlation for the other gating parameters. For peak I_{Na} density, 48/49 variants had
396 concordant results between the two sites (considering each variant as having normal or
397 abnormal function). Future functional assays may benefit from testing at independent sites to
398 demonstrate reproducibility prior to clinical use.

399

400 **The calibrated assay can discriminate between variant controls**

401 We describe two implementations of the assay, one that integrates peak I_{Na} density and
402 gating measurements, and a second that uses a single parameter (peak I_{Na} density
403 measured from a physiological holding potential). Both implementations yielded concordant
404 results in nearly all variant controls (24/25 B and 23/24 P/LP for implementation 1, 25/25 B
405 and 23/24 for implementation 2). After OddsPath calculations as recommended by the
406 ClinGen SVI working group,¹⁸ both implementations of the assay attained strong levels of
407 evidence for both PS3 (abnormal function) and BS3 (normal function).⁸

408 Two variant controls had discordant results with their clinical classifications in the peak I_{Na}
409 and gating assay, p.Ser216Leu and p.Arg1643Cys. The B variant p.Ser216Leu had partial
410 LOF in peak I_{Na} ($Z = -3.39$ with holding at -120 mV). In the -90 mV holding potential
411 measurement, the Z -score was increased to $Z = -1.72$ and fell within the normal-function
412 range (Z within ± 2). A previous report also measured partial LOF for this variant in HEK293
413 cells.³⁸ In addition, this variant has also been reported to have late current in HEK293 cells.³⁹
414 p.Ser216Leu is present in the population at a much higher than expected frequency for a
415 highly penetrant disease-associated variant (allele frequency $> 0.05\%$ in gnomAD).⁴⁰
416 However, p.Ser216Leu has also been observed in multiple patients with arrhythmia
417 phenotypes, including BrS,^{38,41,42} Type 3 Long QT syndrome,^{43,44} Sudden Infant Death
418 Syndrome,^{39,45,46} and atrial fibrillation.^{47,48} Given the multiple arrhythmia reports and the
419 borderline partial LOF phenotype of the variant, p.Ser216Leu may be a risk allele for
420 arrhythmia phenotypes, analogous to *KCNE1* p.Asp85Asn.⁴⁹ The LP variant p.Arg1643Cys
421 also had a discordant outcome in our assay, with a functionally normal range peak current (Z
422 $= -0.71$ and $Z = -0.88$ with holding potentials of -120 mV and -90 mV, respectively). The only
423 aberrant functional phenotype was a depolarized shift in SSA ($+4.31$ mV, $Z = 3.15$),
424 consistent with previous findings.⁵⁰ p.Arg1643Cys has been previously reported in multiple
425 BrS cases⁵⁰⁻⁵³ and we classified it as LP (PS4_moderate, PM5, PM2_supporting, PP3).
426 Although p.Arg1643Cys was absent from gnomAD v2.1.1 and v3.1.2 used in this study, it is

427 present in gnomAD v4 (allele count of 4/86,258 alleles in the South Asian population). Future
428 work could further investigate the functional impact of p.Ser216Leu and p.Arg1643Cys on
429 channel function in other contexts and cell models (e.g. cardiomyocytes) and help further
430 clarify their disease risk.

431

432 **Incorporation of gating changes as well as current density measurements**

433 Peak current is the strongest molecular correlate of BrS and has been associated with risk of
434 events and disease penetrance.^{21,54} Most patch clamp studies of *SCN5A* have used a
435 resting membrane potential of -120 mV in activation protocols to ensure that nearly all
436 channels were closed at the start of the measurement. However, this configuration might
437 overestimate the available peak I_{Na} for BrS-associated *SCN5A* variants that affect $Na_v1.5$
438 gating. Some studies have also evaluated the impact of using a resting potential of -90 mV,
439 which is similar to the resting potential of human cardiomyocytes.⁵⁵⁻⁵⁷ The present study
440 examined peak current density for variants at resting potentials of both -120 mV and at -90
441 mV.

442 When compared to a holding membrane potential of -120 mV, three variants (p.Arg1631Cys,
443 p.Arg1631His and p.Glu1783Lys) had relatively greater reduction in current density when
444 measured with a holding membrane potential of -90 mV (Table 1; Figure 5). These three
445 variants also had altered gating properties in our study (Table 1) and previous reports.^{17,55-61}
446 Altered gating can impact current density by reducing channel availability. Hyperpolarizing
447 shifts in SSI can lead to channels that are not completely inactivated at physiological
448 membrane potentials (and therefore also cannot RFI) and delayed RFI can weaken
449 subsequent activations. As such, holding the resting membrane potential at -90 mV offers
450 more physiologically-relevant functional evaluations while holding membrane potentials at -
451 120 mV enable the scrutiny of gating parameters that may underlie the abnormal function
452 detected at -90 mV.

453

454 **Translational Impact of *SCN5A* APC Assays**

455 Our validated assay was used to assess the function of *SCN5A* variants observed in patients
456 with suspected Brugada Syndrome or other severe arrhythmia phenotypes through
457 collaboration with their primary medical teams. After functional data were provided to each
458 clinical care site, local multi-disciplinary teams performed variant reclassification according to
459 their interpretations of the ACMG framework. Three of the four examined VUS had abnormal
460 function, and addition of this functional data resulted in all three of these variants being
461 reclassified to LP. We anticipate that our calibrated assay will be used in the future to
462 characterize additional *SCN5A* VUS detected in cases of suspected BrS or other
463 arrhythmias associated with *SCN5A* LOF.

464

465 **Limitations**

466 *SCN5A* is associated with various other cardiac phenotypes besides BrS, such as long QT
467 syndrome, dilated cardiomyopathy, familial atrial fibrillation, and sick sinus syndrome.^{2,58,62,63}
468 Although our APC assay could likely be used to detect other types of $\text{Na}_v1.5$ dysfunction,
469 this study only examined the *SCN5A*-BrS relationship linked to $\text{Na}_v1.5$ LOF variants.⁷ To
470 enable high-throughput studies, HEK293 cell lines were employed for experiments rather
471 than induced pluripotent stem cell-derived cardiomyocytes or animal models. These models
472 may be more physiologically accurate but are more costly and at the present are lower
473 throughput than heterologous expression experiments.⁶⁴ *SCN5A* function can be influenced
474 by several features not modelled in our study, including alternative spliced isoforms,⁶⁵ or
475 expression of additional genes such as β -subunits^{39,65,66} or transcription factors.⁵ Despite
476 these limitations, the assay was still able to accurately distinguish benign from pathogenic
477 variant controls.

478

479 **Future Directions**

480 Additional known and yet to be discovered *SCN5A* VUS could be studied using our
481 calibrated functional assay. Further investigations of the two variants with discordant assay
482 results may reveal new biological mechanisms. Further implementation of multi-site
483 replication and calibration for additional genes and disorders will broaden the impact of APC
484 assays for precision medicine.

485

486

487 **Declarations**

488 **Acknowledgements**

489 We thank Kenneth Matreyek and Doug Fowler for the HEK293 landing pad cells, and Lorena
490 Harvey, Maria Calandranis, and Paige Roberson with *SCN5A* cloning assistance and cell
491 preparation. Figure 1 was created with BioRender.

492

493 **Authors' contributions**

494 JM, MO, JV, CN and AG contributed to the original research and analyses, drafting, and
495 editing this paper. EB, KT, JI, AM, JS, GD, KA, BS, AS, BF, KD, VP, HC, MP and DR
496 contributed additional genetic and clinical expertise, and helped edit the paper. All authors
497 approved the final manuscript.

498

499 **Declaration of interests**

500 Dr. Glazer is a consultant for BioMarin, Inc. Victoria Parikh is a scientific advisory board
501 member (Lexeo Therapeutics), clinical advisor (Constantiam Biosciences) and consultant
502 (BioMarin, Inc., Viz.ai). Victoria Parikh also receives research support from BioMarin, Inc.
503 Remaining authors declare no competing interests.

504

505 **Ethics approval and consent to participate**

506 The University of Washington Human Subjects Division, Institutional Review Board,
507 BioMedical Committee B reviewed and granted approval for the BBI-CVD study # 14771.
508 The University of Washington's IRB FWA # is #00006878. The IRB granted expedited
509 approval for the study with consent, HIPAA authorization, parental permission and assent
510 waived, and involvement of children was approved. Stanford University School of Medicine
511 IRB gave ethical approval, and patient consent was waived based on removal of all PHI.
512 Vanderbilt University Medical Center IRB granted approval #9047. Additionally, signed
513 informed consent was received from patient. Clinical case from The Royal Melbourne
514 Hospital does not have IRB/REC as it is not an enrolled patient however, patient consent for
515 publication was received.

516

517 **Availability of data and materials**

518 All functional data are available in the accompanying Supplement and Supplementary files in
519 .csv format. Code used to process these files is available at <https://github.com/GlazerLab/>
520 and <https://github.com/VCCRI/>. Individual clinical data beyond those presented in the
521 manuscript are withheld for patient privacy. Variant classifications and functional data will be
522 uploaded to ClinVar upon publication.

523

524 **Funding**

525 This study was funded by the National Institutes of Health (NIH): R01 HL164675 (DMR), R01
526 HL149826 (DMR), R00 HG010904 (AMG), R01 HG013025 (ABS), and R35 GM150465
527 (AMG), a New South Wales Cardiovascular Disease Senior Scientist grant (JIV), and a
528 MRFF Genomics Health Futures Mission grant MRF2016760 (JIV and CAN). MJO received
529 support from NIH grants F30HL163923 and T32GM007347. We also acknowledge support
530 from the Victor Chang Cardiac Research Institute Innovation Centre, funded by the NSW
531 Government. VUMC flow cytometry experiments were performed in the Vanderbilt Flow
532 Cytometry Shared Resource. The Vanderbilt Flow Cytometry Shared Resource is supported
533 by the Vanderbilt Ingram Cancer Center (NIH P30 CA68485) and the Vanderbilt Digestive
534 Disease Research Center (NIH DK058404). The VUMC Nanion SyncroPatch 384PE is
535 housed and managed within the Vanderbilt High-Throughput Screening Core Facility, an
536 institutionally supported core, and was funded by NIH Shared Instrumentation Grant
537 1S10OD025281. The HTS Core receives support from the Vanderbilt Institute of Chemical
538 Biology and the Vanderbilt Ingram Cancer Center (NIH P30 CA68485).

539

540

541 References

- 542 1. Brugada, P., and Brugada, J. (1992). Right bundle branch block, persistent ST segment
543 elevation and sudden cardiac death: A distinct clinical and electrocardiographic
544 syndrome: A multicenter report. *Journal of the American College of Cardiology* 20,
545 1391-1396.
- 546 2. Amin, A.S., Asghari-Roodsari, A., and Tan, H.L. (2010). Cardiac sodium channelopathies.
547 *Pflugers Arch* 460, 223-237.
- 548 3. Cerrone, M., Costa, S., and Delmar, M. (2022). The Genetics of Brugada Syndrome. *Annu*
549 *Rev Genomics Hum Genet*.
- 550 4. Hosseini, S.M., Kim, R., Udupa, S., Costain, G., Jobling, R., Liston, E., Jamal, S.M.,
551 Szybowska, M., Morel, C.F., Bowdin, S., et al. (2018). Reappraisal of Reported
552 Genes for Sudden Arrhythmic Death. *Circulation* 138, 1195-1205.
- 553 5. Barc, J., Tadros, R., Glinge, C., Chiang, D.Y., Jouni, M., Simonet, F., Jurgens, S.J.,
554 Baudic, M., Nicastro, M., Potet, F., et al. (2022). Genome-wide association analyses
555 identify new Brugada syndrome risk loci and highlight a new mechanism of sodium
556 channel regulation in disease susceptibility. *Nature Genetics* 54, 232-239.
- 557 6. Musunuru, K., Hershberger, R.E., Day, S.M., Klinedinst, N.J., Landstrom, A.P., Parikh,
558 V.N., Prakash, S., Semsarian, C., and Sturm, A.C. (2020). Genetic Testing for
559 Inherited Cardiovascular Diseases: A Scientific Statement From the American Heart
560 Association. *Circulation: Genomic and Precision Medicine* 13, e000067.
- 561 7. Wilde, A.A.M., Semsarian, C., Márquez, M.F., Sepehri Shamloo, A., Ackerman, M.J.,
562 Ashley, E.A., Sternick, E.B., Barajas-Martinez, H., Behr, E.R., Bezzina, C.R., et al.
563 (2022). European Heart Rhythm Association (EHRA)/Heart Rhythm Society
564 (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm
565 Society (LAHRS) Expert Consensus Statement on the state of genetic testing for
566 cardiac diseases. *EP Europace* 24, euac030.
- 567 8. Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W.W., Hegde,
568 M., Lyon, E., Spector, E., et al. (2015). Standards and guidelines for the
569 interpretation of sequence variants: a joint consensus recommendation of the
570 American College of Medical Genetics and Genomics and the Association for
571 Molecular Pathology. *Genetics in Medicine* 17, 405-423.
- 572 9. Landrum, M.J., Chitipiralla, S., Brown, G.R., Chen, C., Gu, B., Hart, J., Hoffman, D., Jang,
573 W., Kaur, K., Liu, C., et al. (2019). ClinVar: improvements to accessing data. *Nucleic*
574 *Acids Research* 48, D835-D844.
- 575 10. Landrum, M.J., Lee, J.M., Benson, M., Brown, G.R., Chao, C., Chitipiralla, S., Gu, B.,
576 Hart, J., Hoffman, D., Jang, W., et al. (2018). ClinVar: improving access to variant
577 interpretations and supporting evidence. *Nucleic Acids Res* 46, D1062-d1067.
- 578 11. Ackerman, M.J. (2015). Genetic purgatory and the cardiac channelopathies: Exposing
579 the variants of uncertain/unknown significance issue. *Heart Rhythm* 12, 2325-2331.
- 580 12. Ackerman, J.P., Bartos, D.C., Kapplinger, J.D., Tester, D.J., Delisle, B.P., and
581 Ackerman, M.J. (2016). The Promise and Peril of Precision Medicine: Phenotyping
582 Still Matters Most. *Mayo Clin Proc*.
- 583 13. Vanoye, C.G., Desai, R.R., Fabre, K.L., Gallagher, S.L., Potet, F., DeKeyser, J.-M.,
584 Macaya, D., Meiler, J., Sanders, C.R., and George, A.L. (2018). High-Throughput
585 Functional Evaluation of KCNQ1 Decrypts Variants of Unknown Significance.
586 *Circulation: Genomic and Precision Medicine* 11, e002345.
- 587 14. Vanoye, C.G., Desai, R.R., Ji, Z., Adusumilli, S., Jairam, N., Ghabra, N., Joshi, N., Fitch,
588 E., Helbig, K.L., McKnight, D., et al. (2022). High-throughput evaluation of epilepsy-
589 associated KCNQ2 variants reveals functional and pharmacological heterogeneity.
590 *JCI Insight* 7.
- 591 15. Ng, C.-A., Perry, M.D., Liang, W., Smith, N.J., Foo, B., Shrier, A., Lukacs, G.L., Hill, A.P.,
592 and Vandenberg, J.I. (2020). High-throughput phenotyping of heteromeric human

- 593 ether-à-go-go-related gene potassium channel variants can discriminate pathogenic
594 from rare benign variants. *Heart Rhythm* 17, 492-500.
- 595 16. Jiang, C., Richardson, E., Farr, J., Hill, A.P., Ullah, R., Kroncke, B.M., Harrison, S.M.,
596 Thomson, K.L., Ingles, J., Vandenberg, J.I., et al. (2022). A calibrated functional
597 patch-clamp assay to enhance clinical variant interpretation in KCNH2-related long
598 QT syndrome. *Am J Hum Genet* 109, 1199-1207.
- 599 17. Glazer, A.M., Wada, Y., Li, B., Muhammad, A., Kalash, O.R., O'Neill, M.J., Shields, T.,
600 Hall, L., Short, L., Blair, M.A., et al. (2020). High-Throughput Reclassification of
601 SCN5A Variants. *Am J Hum Genet* 107, 111-123.
- 602 18. Brnich, S.E., Abou Tayoun, A.N., Couch, F.J., Cutting, G.R., Greenblatt, M.S., Heinen,
603 C.D., Kanavy, D.M., Luo, X., McNulty, S.M., Starita, L.M., et al. (2020).
604 Recommendations for application of the functional evidence PS3/BS3 criterion using
605 the ACMG/AMP sequence variant interpretation framework. *Genome Med* 12, 3.
- 606 19. Thomson, K.L., Jiang, C., Richardson, E., Westphal, D.S., Burkard, T., Wolf, C.M., Vatta,
607 M., Harrison, S.M., Ingles, J., Bezzina, C.R., et al. (2023). Clinical interpretation of
608 KCNH2 variants using a robust PS3/BS3 functional patch clamp assay. medRxiv,
609 2023.2010.2008.23296707.
- 610 20. Morales, J., Pujar, S., Loveland, J.E., Astashyn, A., Bennett, R., Berry, A., Cox, E.,
611 Davidson, C., Ermolaeva, O., Farrell, C.M., et al. (2022). A joint NCBI and EMBL-EBI
612 transcript set for clinical genomics and research. *Nature* 604, 310-315.
- 613 21. Kroncke, B.M., Glazer, A.M., Smith, D.K., Blume, J.D., and Roden, D.M. (2018). SCN5A
614 (NaV1.5) Variant Functional Perturbation and Clinical Presentation: Variants of a
615 Certain Significance. *Circulation: Genomic and Precision Medicine* 11, e002095.
- 616 22. Karczewski, K.J., Francioli, L.C., Tiao, G., Cummings, B.B., Alföldi, J., Wang, Q., Collins,
617 R.L., Laricchia, K.M., Ganna, A., Birnbaum, D.P., et al. (2020). The mutational
618 constraint spectrum quantified from variation in 141,456 humans. *Nature* 581, 434-
619 443.
- 620 23. Whiffin, N., Minikel, E., Walsh, R., O'Donnell-Luria, A.H., Karczewski, K., Ing, A.Y.,
621 Barton, P.J.R., Funke, B., Cook, S.A., MacArthur, D., et al. (2017). Using high-
622 resolution variant frequencies to empower clinical genome interpretation. *Genet Med*
623 19, 1151-1158.
- 624 24. Vutthikraivit, W., Rattanawong, P., Putthapiban, P., Sukhumthamarat, W.,
625 Vathesatogkit, P., Ngarmukos, T., and Thakkinstian, A. (2018). Worldwide
626 Prevalence of Brugada Syndrome: A Systematic Review and Meta-Analysis. *Acta*
627 *Cardiol Sin* 34, 267-277.
- 628 25. Ghosh, R., Harrison, S.M., Rehm, H.L., Plon, S.E., and Biesecker, L.G. (2018). Updated
629 recommendation for the benign stand-alone ACMG/AMP criterion. *Hum Mutat* 39,
630 1525-1530.
- 631 26. Tavtigian, S.V., Greenblatt, M.S., Harrison, S.M., Nussbaum, R.L., Prabhu, S.A.,
632 Boucher, K.M., and Biesecker, L.G. (2018). Modeling the ACMG/AMP variant
633 classification guidelines as a Bayesian classification framework. *Genet Med* 20,
634 1054-1060.
- 635 27. Walsh, R., Lahrouchi, N., Tadros, R., Kyndt, F., Glinge, C., Postema, P.G., Amin, A.S.,
636 Nannenberg, E.A., Ware, J.S., Whiffin, N., et al. (2021). Enhancing rare variant
637 interpretation in inherited arrhythmias through quantitative analysis of consortium
638 disease cohorts and population controls. *Genetics in Medicine* 23, 47-58.
- 639 28. Ioannidis, N.M., Rothstein, J.H., Pejaver, V., Middha, S., McDonnell, S.K., Baheti, S.,
640 Musolf, A., Li, Q., Holzinger, E., Karyadi, D., et al. (2016). REVEL: An Ensemble
641 Method for Predicting the Pathogenicity of Rare Missense Variants. *The American*
642 *Journal of Human Genetics* 99, 877-885.
- 643 29. Kopanos, C., Tsiolkas, V., Kouris, A., Chapple, C.E., Albarca Aguilera, M., Meyer, R.,
644 and Massouras, A. (2018). VarSome: the human genomic variant search engine.
645 *Bioinformatics* 35, 1978-1980.
- 646 30. Ng, C.A., Farr, J., Young, P., Windley, M.J., Perry, M.D., Hill, A.P., and Vandenberg, J.I.
647 (2021). Heterozygous KCNH2 variant phenotyping using Flp-In HEK293 and high-

- 648 throughput automated patch clamp electrophysiology. *Biol Methods Protoc* 6,
649 bpab003.
- 650 31. O'Neill, M.J., Muhammad, A., Li, B., Wada, Y., Hall, L., Solus, J.F., Short, L., Roden,
651 D.M., and Glazer, A.M. (2022). Dominant negative effects of SCN5A missense
652 variants. *Genetics in Medicine*.
- 653 32. Matreyek, K.A., Stephany, J.J., Chiasson, M.A., Hasle, N., and Fowler, D.M. (2020). An
654 improved platform for functional assessment of large protein libraries in mammalian
655 cells. *Nucleic Acids Res* 48, e1.
- 656 33. Hermann, M., Stillhard, P., Wildner, H., Seruggia, D., Kapp, V., Sánchez-Iranzo, H.,
657 Mercader, N., Montoliu, L., Zeilhofer, H.U., and Pelczar, P. (2014). Binary
658 recombinase systems for high-resolution conditional mutagenesis. *Nucleic Acids Res*
659 42, 3894-3907.
- 660 34. Ng, C.-A., Ullah, R., Farr, J., Hill, A.P., Kozek, K.A., Vanags, L.R., Mitchell, D.W.,
661 Kroncke, B.M., and Vandenberg, J.I. (2022). A massively parallel assay accurately
662 discriminates between functionally normal and abnormal variants in a hotspot domain
663 of KCNH2. *The American Journal of Human Genetics* 109, 1208-1216.
- 664 35. Grant, A.O. (2009). Cardiac Ion Channels. *Circulation: Arrhythmia and Electrophysiology*
665 2, 185-194.
- 666 36. Li, W., Yin, L., Shen, C., Hu, K., Ge, J., and Sun, A. (2018). SCN5A Variants:
667 Association With Cardiac Disorders. *Front Physiol* 9, 1372.
- 668 37. Glazer, A.M., Davogustto, G.E., Shaffer, C.M., Vanoye, C.G., Desai, R.R., Farber-Eger,
669 E., Dikilitas, O., Shang, N., Pacheco, J.A., Yang, T., et al. (2022). Arrhythmia Variant
670 Associations and Reclassifications in the eMERGE-III Sequencing Study. *Circulation*
671 0, 877-891.
- 672 38. Marangoni, S., Di Resta, C., Rocchetti, M., Barile, L., Rizzetto, R., Summa, A., Severi,
673 S., Sommariva, E., Pappone, C., Ferrari, M., et al. (2011). A Brugada syndrome
674 mutation (p.S216L) and its modulation by p.H558R polymorphism: standard and
675 dynamic characterization. *Cardiovascular Research* 91, 606-616.
- 676 39. Wang, D.W., Desai, R.R., Crotti, L., Arnestad, M., Insolia, R., Pedrazzini, M., Ferrandi,
677 C., Vege, A., Rognum, T., Schwartz, P.J., et al. (2007). Cardiac Sodium Channel
678 Dysfunction in Sudden Infant Death Syndrome. *Circulation* 115, 368-376.
- 679 40. Chen, S., Francioli, L.C., Goodrich, J.K., Collins, R.L., Kanai, M., Wang, Q., Alföldi, J.,
680 Watts, N.A., Vittal, C., Gauthier, L.D., et al. (2022). A genome-wide mutational
681 constraint map quantified from variation in 76,156 human genomes. *bioRxiv*,
682 2022.2003.2020.485034.
- 683 41. Sommariva, E., Pappone, C., Martinelli Boneschi, F., Di Resta, C., Rosaria Carbone, M.,
684 Salvi, E., Vergara, P., Sala, S., Cusi, D., Ferrari, M., et al. (2013). Genetics can
685 contribute to the prognosis of Brugada syndrome: a pilot model for risk stratification.
686 *Eur J Hum Genet* 21, 911-917.
- 687 42. Crotti, L., Marcou, C.A., Tester, D.J., Castelletti, S., Giudicessi, J.R., Torchio, M.,
688 Medeiros-Domingo, A., Simone, S., Will, M.L., Dagradi, F., et al. (2012). Spectrum
689 and prevalence of mutations involving BrS1- through BrS12-susceptibility genes in a
690 cohort of unrelated patients referred for Brugada syndrome genetic testing:
691 implications for genetic testing. *J Am Coll Cardiol* 60, 1410-1418.
- 692 43. Ortiz-Bonnin, B., Rinné, S., Moss, R., Streit, A.K., Scharf, M., Richter, K., Stöber, A.,
693 Pfeufer, A., Seemann, G., Käab, S., et al. (2016). Electrophysiological
694 characterization of a large set of novel variants in the SCN5A-gene: identification of
695 novel LQTS3 and BrS mutations. *Pflügers Archiv - European Journal of Physiology*
696 468, 1375-1387.
- 697 44. Shestak, A.G., Makarov, L.M., Komoliatova, V.N., Kolesnikova, I.V., Skorodumova, L.O.,
698 Generozov, E.V., and Zaklyazminskaya, E.V. (2021). Coexistence of Two Rare
699 Genetic Variants in Canonical and Non-canonical Exons of SCN5A: A Potential
700 Source of Misinterpretation. *Frontiers in Genetics* 12, 722291.
- 701 45. Arnestad, M., Crotti, L., Rognum, T.O., Insolia, R., Pedrazzini, M., Ferrandi, C., Vege, A.,
702 Wang, D.W., Rhodes, T.E., George, A.L., et al. (2007). Prevalence of Long-QT

- 703 Syndrome Gene Variants in Sudden Infant Death Syndrome. *Circulation* 115, 361-
704 367.
- 705 46. Paludan-Müller, C., Ghouse, J., Vad, O.B., Herfelt, C.B., Lundegaard, P., Ahlberg, G.,
706 Schmitt, N., Svendsen, J.H., Haunsø, S., Bundgaard, H., et al. (2019). Reappraisal of
707 variants previously linked with sudden infant death syndrome: results from three
708 population-based cohorts. *Eur J Hum Genet* 27, 1427-1435.
- 709 47. Olesen, M.S., Yuan, L., Liang, B., Holst, A.G., Nielsen, N., Nielsen, J.B., Hedley, P.L.,
710 Christiansen, M., Olesen, S.P., Haunso, S., et al. (2012). High prevalence of long QT
711 syndrome-associated SCN5A variants in patients with early-onset lone atrial
712 fibrillation. *Circ Cardiovasc Genet* 5, 450-459.
- 713 48. Darbar, D., Kannankeril, P.J., Donahue, B.S., Kucera, G., Stubblefield, T., Haines, J.L.,
714 George, A.L., and Roden, D.M. (2008). Cardiac Sodium Channel (SCN5A) Variants
715 Associated with Atrial Fibrillation. *Circulation* 117, 1927-1935.
- 716 49. Lane, C.M., Giudicessi, J.R., Ye, D., Tester, D.J., Rohatgi, R.K., Bos, J.M., and
717 Ackerman, M.J. (2018). Long QT syndrome type 5-Lite: Defining the clinical
718 phenotype associated with the potentially proarrhythmic p.Asp85Asn-KCNE1
719 common genetic variant. *Heart Rhythm* 15, 1223-1230.
- 720 50. Frustaci, A., Priori, S.G., Pieroni, M., Chimenti, C., Napolitano, C., Rivolta, I., Sanna, T.,
721 Bellocci, F., and Russo, M.A. (2005). Cardiac Histological Substrate in Patients With
722 Clinical Phenotype of Brugada Syndrome. *Circulation* 112, 3680-3687.
- 723 51. Yamagata, K., Horie, M., Aiba, T., Ogawa, S., Aizawa, Y., Ohe, T., Yamagishi, M.,
724 Makita, N., Sakurada, H., Tanaka, T., et al. (2017). Genotype-Phenotype Correlation
725 of SCN5A Mutation for the Clinical and Electrocardiographic Characteristics of
726 Probands With Brugada Syndrome. *Circulation* 135, 2255-2270.
- 727 52. Frustaci, A., Russo, M.A., and Chimenti, C. (2009). Structural myocardial abnormalities
728 in asymptomatic family members with Brugada syndrome and SCN5A gene
729 mutation. *Eur Heart J* 30, 1763.
- 730 53. Savastano, S., Rordorf, R., Vicentini, A., Petracci, B., Taravelli, E., Castelletti, S.,
731 D'Errico, A., Torchio, M., Dossena, C., Novara, P., et al. (2014). A comprehensive
732 electrocardiographic, molecular, and echocardiographic study of Brugada syndrome:
733 validation of the 2013 diagnostic criteria. *Heart Rhythm* 11, 1176-1183.
- 734 54. Han, D., Tan, H., Sun, C., and Li, G. (2018). Dysfunctional Nav1.5 channels due to
735 SCN5A mutations. *Exp Biol Med (Maywood)* 243, 852-863.
- 736 55. Benson, D.W., Wang, D.W., Dymont, M., Knilans, T.K., Fish, F.A., Strieper, M.J.,
737 Rhodes, T.H., and George, A.L., Jr. (2003). Congenital sick sinus syndrome caused
738 by recessive mutations in the cardiac sodium channel gene (SCN5A). *J Clin Invest*
739 112, 1019-1028.
- 740 56. Nakajima, T., Kaneko, Y., Saito, A., Ota, M., Iijima, T., and Kurabayashi, M. (2015).
741 Enhanced fast-inactivated state stability of cardiac sodium channels by a novel
742 voltage sensor SCN5A mutation, R1632C, as a cause of atypical Brugada syndrome.
743 *Heart Rhythm* 12, 2296-2304.
- 744 57. Makita, N., Behr, E., Shimizu, W., Horie, M., Sunami, A., Crotti, L., Schulze-Bahr, E.,
745 Fukuhara, S., Mochizuki, N., Makiyama, T., et al. (2008). The E1784K mutation in
746 SCN5A is associated with mixed clinical phenotype of type 3 long QT syndrome. *J*
747 *Clin Invest* 118, 2219-2229.
- 748 58. Gui, J., Wang, T., Jones, R.P., Trump, D., Zimmer, T., and Lei, M. (2010). Multiple loss-
749 of-function mechanisms contribute to SCN5A-related familial sick sinus syndrome.
750 *PLoS One* 5, e10985.
- 751 59. Deschênes, I., Baroudi, G., Berthet, M., Barde, I., Chalvidan, T., Denjoy, I., Guicheney,
752 P., and Chahine, M. (2000). Electrophysiological characterization of SCN5A
753 mutations causing long QT (E1784K) and Brugada (R1512W and R1432G)
754 syndromes. *Cardiovasc Res* 46, 55-65.
- 755 60. Abdelsayed, M., Baruteau, A.E., Gibbs, K., Sanatani, S., Krahn, A.D., Probst, V., and
756 Ruben, P.C. (2017). Differential calcium sensitivity in Na(V) 1.5 mixed syndrome
757 mutants. *J Physiol* 595, 6165-6186.

- 758 61. Veltmann, C., Barajas-Martinez, H., Wolpert, C., Borggreffe, M., Schimpf, R., Pfeiffer, R.,
759 Cáceres, G., Burashnikov, E., Antzelevitch, C., and Hu, D. (2016). Further Insights in
760 the Most Common SCN5A Mutation Causing Overlapping Phenotype of Long QT
761 Syndrome, Brugada Syndrome, and Conduction Defect. *Journal of the American*
762 *Heart Association* 5, e003379.
- 763 62. Pérez-Riera, A.R., Barbosa-Barros, R., Daminello Raimundo, R., da Costa de Rezende
764 Barbosa, M.P., Esposito Sorpreso, I.C., and de Abreu, L.C. (2018). The congenital
765 long QT syndrome Type 3: An update. *Indian Pacing Electrophysiol J* 18, 25-35.
- 766 63. Moreau, A., Gosselin-Badaroudine, P., Boutjdir, M., and Chahine, M. (2015). Mutations
767 in the Voltage Sensors of Domains I and II of Nav1.5 that are Associated with
768 Arrhythmias and Dilated Cardiomyopathy Generate Gating Pore Currents. *Front*
769 *Pharmacol* 6, 301.
- 770 64. Sendfeld, F., Selga, E., Scornik, F.S., Pérez, G.J., Mills, N.L., and Brugada, R. (2019).
771 Experimental Models of Brugada syndrome. *Int J Mol Sci* 20.
- 772 65. Tan, B.H., Valdivia, C.R., Rok, B.A., Ye, B., Ruwaldt, K.M., Tester, D.J., Ackerman, M.J.,
773 and Makielski, J.C. (2005). Common human SCN5A polymorphisms have altered
774 electrophysiology when expressed in Q1077 splice variants. *Heart Rhythm* 2, 741-
775 747.
- 776 66. Watanabe, H., Darbar, D., Kaiser, D.W., Jiramongkolchai, K., Chopra, S., Donahue,
777 B.S., Kannankeril, P.J., and Roden, D.M. (2009). Mutations in sodium channel β 1-
778 and β 2-subunits associated with atrial fibrillation. *Circ Arrhythm Electrophysiol* 2, 268-
779 275.

780

781

782 **Figures**

783 **Figure 1: A Calibrated *SCN5A* Automated Patch Clamp Assay.**

784 (A) Overview of project design. Selection of calibration variants, independent execution of
785 experiments at two sites, calibration of results, and application to clinical cases. (B)
786 Individual site assay schematic. Minor differences in cell systems, selection drugs, and APC
787 conditions/analysis existed between sites and are described in the Methods.

788

789

790 **Figure 2: Establishing an *SCN5A* voltage protocol and data transformation for normal**
791 **distribution.**

792 (A) Example traces from a single cell expressing WT *SCN5A* illustrating sodium
793 conductance following activation from -100 mV to +60 mV in +5 mV increments. The -30 mV
794 sweep is highlighted in orange and was used for analyses. (B) Current-voltage curves show
795 current densities at voltages -100 mV to +60 mV for WT (blue) and negative cell lines (grey).
796 Mean \pm 95% confidence interval values are shown. (C-D) Violin plot of WT *SCN5A* current
797 density at each site (VCCRI N = 609; VUMC N = 2,118 cells). The current density of WT
798 *SCN5A* did not follow a normal distribution ($W = 0.956$ and $W = 0.942$ at VCCRI and VUMC,
799 respectively; Shapiro-Wilk test). The median value and 1st and 3rd quartiles are indicated with
800 red lines. (E-F) Violin plots of WT *SCN5A* current density at each site after square root
801 transformation. The square root-transformed current densities more closely followed a
802 normal distribution ($W = 0.997$ and $W = 0.995$ at VCCRI and VUMC, respectively; Shapiro-
803 Wilk test). The median value and 1st and 3rd quartiles are indicated with blue lines. The
804 resulting mean \pm SD of the square root-transformed distribution was 100 ± 29.2 (VCCRI) and
805 100 ± 34.1 (VUMC).

806

807

808 **Figure 3: Distinguishing pathogenic and likely pathogenic variants from benign**
809 **variants with Nav1.5 peak current density measurements.**

810 (A-C) Square-root transformed, normalized peak current densities at -30mV obtained by
811 VCCRI (94.1 ± 13.9 ; A), VUMC (94.8 ± 11.1 ; B) and a combined dataset (94.2 ± 10.3 ; C).
812 SCN5A peak I_{Na} densities (pA/pF) were measured after holding at -120 mV. The normal
813 functional range was defined as the mean ± 2 SD of the benign variant values (blue region).
814 The peak current measurements distinguished the P/LP and B variants, apart from three
815 variants (p.Ser216Leu, p.Arg1631His, and p.Arg1643Cys) discussed further in the text. (D)
816 Peak current densities from the two sites were highly correlated ($p < 0.0001$; $R^2 = 0.86$). (E)
817 Violin plot summary of combined current densities among B and P/LP variants. Blue-filled
818 circles (●) indicated B variant controls. Red-filled circles (●) indicates P/LP variant controls.
819 Data is presented as mean \pm 95% CI.

820

821

822 **Figure 4: Analysis of channel gating parameters reveals variants that affect gating.**

823 (A) SSA of p.Ala735Val compared to WT, showing a right-shift in voltage of activation.
824 Boltzmann best-fit curves are plotted. (B) Steady-state voltage of half-activation difference
825 from wildtype (SSA ΔV_{50}) for variant controls. Combined SSA $\Delta V_{50} = -0.37 \pm 1.71$. ΔV_{50}
826 represents the shift in voltage where variants are half activated, as compared to WT. (C) SSI
827 of p.Arg1631Cys compared to WT, showing a left-shift in voltage of inactivation. Boltzmann
828 best-fit curves are plotted. (D) Steady-state voltage of half-inactivation difference from
829 wildtype (SSI ΔV_{50}) for variant controls. Combined SSI $\Delta V_{50} = -0.37 \pm 1.71$. ΔV_{50} represents
830 the shift in voltage where variants are half inactivated, as compared to WT. (E) RFI of
831 p.Arg1631His compared to WT, showing a large delay in recovery post inactivation. Double
832 exponential best-fit curves are plotted. (F) RFI difference from WT (ΔT_{50}). Combined RFI

833 $\Delta T_{50} = 0.933 \pm 1.77$. ΔT_{50} represents the shift in time required for channels to reach a half-
834 recovered from inactivation state as compared to WT. Many P/LP control variants did not
835 have sufficient peak current to measure the three parameters shown in this figure. (G)
836 Sample radar plots for corresponding variants with extreme shifts in gating parameters:
837 p.Ala735Val (SSA), p.Arg1631Cys (SSI) and p.Arg1631His (RFI). Radar plots for all
838 analyzed variants are presented in Figure S5. Blue-filled circles (●) indicated B variant
839 controls. Red-filled circles (●) indicates P/LP variant controls. In panels B, D, F, G, H and I,
840 the dashed line represents $Z = 0$, and the blue region indicates Z-scores within ± 2 . In panels
841 B, D and F, and the dotted lines indicate Z outside of ± 4 . Data is presented as mean \pm 95%
842 CI.

843

844

845 **Figure 5: Current density measured from a physiological resting potential is a single**
846 **variable that distinguishes benign from pathogenic variants.**

847 (A) Protocol showing holding voltages of -120 mV -90 mV for 500 ms prior to activation of
848 channels. Sample raw traces showing current measured with holding potentials of -120 mV
849 and -90 mV for the same variant cell when depolarized to -30 mV. (B) Correlation between
850 the different holding membrane voltages show strong correlation ($R^2=0.95$), with outliers
851 p.Arg1631His, p.Arg1631Cys and p.Glu1783Lys. (C) Normalized current density of variant
852 controls activated from a holding voltage of -90 mV to represent the resting membrane
853 potential of human cardiomyocytes encompasses gating parameters such as SSA, SSI and
854 RFI. Mean = 91.7 ± 14.9 . Data is presented as mean \pm 95% CI. Blue-filled circles (●)
855 indicated B variant controls. Red-filled circles (●) indicates P/LP variant controls.

856

857

858 **Figure 6: Evaluation of assay according to ClinGen SVI recommendations for**
859 **functional evidence**

860 (A) Confusion matrix showing sensitivity and specificity of our previously deployed functional
861 assessment combining -120 mV-held peak current ($Z = 2$) and gating ($Z = 4$) properties
862 using data from both sites. (B) BS3_strong and PS3_strong may be applied for this
863 combination of parameters functional assay, following ClinGen guidelines¹⁸. (C) Confusion
864 matrix showing sensitivity and specificity for a single parameter, -90 mV-held peak current (Z
865 = 2) from the VCCRI site. The B variant p.Ser216Leu is concordantly classified in this
866 implementation of the assay. (D) BS3_strong and PS3_strong may be applied for this single
867 parameter functional assay, following ClinGen guidelines¹⁸.

868

869

870 **Figure 7: Reclassification of clinically observed variants with calibrated functional**
871 **data.**

872 (A-D) Four clinical cases of families segregating *SCN5A* VUS. Arrows indicate the proband.
873 Red crosses indicate variant carriers. The sexes of family members have been anonymized
874 as indicated by diamond-shaped symbols. (A) Proband with sudden cardiac arrest and
875 successful out-of-hospital defibrillation, subsequently diagnosed with Brugada Syndrome
876 and Progressive Cardiac Conduction Defect. The *SCN5A* VUS segregated with conduction
877 disease in the proband and the affected parent. There was a family history of cardiac
878 arrests. (B) Proband with syncope and fever-induced Type 1 Brugada pattern on ECG, with
879 a family history of recurrent syncope, seizures, and one cardiac arrest. Family members
880 were hesitant to engage in genetic testing preventing segregation analysis. (C) Pedigree of
881 family members with conduction block, cardiomyopathy, ventricular tachycardia/fibrillation
882 and aborted cardiac arrest. The *SCN5A* VUS segregated with a severe arrhythmia
883 phenotype in the proband and conduction block in his two young children. (D) Proband with

884 spontaneous Type 1 Brugada pattern on a screening ECG, found to have a VUS in *SCN5A*.
 885 (E) ACMG/AMP classification criteria and reclassifications following incorporation of
 886 functional data for the four clinically observed variants. Classifications were performed
 887 independently at each clinical site by a genetic counselor, clinical geneticist, or physician
 888 specializing in genomic medicine.

889

890

891

892 **Table 1: Variants with outlier values for gating parameters**

893

Variant	SSA		SSI		RFI		<i>I_{Na}</i> Density -120 mV hold		<i>I_{Na}</i> Density -90 mV hold	
	ΔV_{50}	Z	ΔV_{50}	Z	ΔT_{50}	Z	Norm (sqrt)	Z	Norm (sqrt)	Z
	p.Ala735Val	15.14	10.54	-4.74	-1.72	9.62	4.91	50.85	-4.19	43.30
p.Glu1224Lys	11.23	7.87	18.03	8.37	-11.90	-7.25	66.63	-2.66	54.98	-2.41
p.Arg1631Cys	7.25	5.16	-28.04	-12.04	129.60	72.74	50.28	-4.25	23.89	-4.45
p.Arg1631His	3.28	2.45	-20.90	-8.87	188.60	106.09	77.67	-1.60	39.41	-3.43
p.Glu1783Lys	8.77	6.19	-10.60	-4.31	0.24	-0.39	52.28	-4.05	26.62	-4.27

894


895 Severe gating changes ($Z > +4$ or $Z < -4$) were observed in five P/LP variants. p.Arg1631His,
 896 which had a had *I_{Na}* density value normal ranges at activation following -120 mV resting
 897 potentials, had a hyperpolarized shifts in SSI and severely delayed RFI. This gating effect
 898 was also visibly incorporated at activation following -90 mV resting potentials. Bolded
 899 numbers indicate measurements outside the benign normal range ($-4 < Z < 4$ for SSA, SSI,
 900 and RFI and $Z < -2$ for *I_{Na}* density).

901

902


A

SCN5A Variant Selection




25 B and 24 P/LP
SCN5A variants for
assay calibration

Data Acquisition




Independent VUMC and
VCCRI experiments
"Institutional Replication"

Data Analysis



Correlate between institutions
Calibrate assay based on
ClinGen OddsPath

Deploy on *SCN5A* VUS Cases



Study and interpret
clinically-observed
SCN5A VUS's

B

Cell System

VUMC



HEK293
Landing Pad

Stable *SCN5A*
line generation

VCCRI



HEK293 Flp-In

Stable *SCN5A*
line generation

Selection




Caspase (-) and
blasticidin (+)










Hygromycin (+)


Growth


Assay












-120 mV Peak and Gating


It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).



B

SCN5A BrS assay	ClinGen SVI Recommendation		
	Calculated OddsPath	Odds of Pathogenicity (OddsPath)	Evidence strength equivalent
Benign variants	0.043	<0.053	BS3_strong
Pathogenic variants	24.0	>18.7	PS3_strong


-90 mV Peak



D


SCN5A BrS assay	ClinGen SVI Recommendation		
	Calculated OddsPath	Odds of Pathogenicity (OddsPath)	Evidence strength equivalent
Benign variants	0.042	<0.053	BS3_strong
Pathogenic variants	24.0	>18.7	PS3_strong

A




Family 1 (p.Asn1378_Lys1379insValPhe)

B




Family 2 (p.Phe1751del)

C



Family 3 (p.Asn932Lys)

D



Family 4 (p.Arg1305Cys)



E

Variant	Population	in silico	Phenotype	Functional	Classification
p.Asn1378_Lys1379insValPhe			PP4	PS3_strong	VUS -> LP
p.Phe1751del	PM2_supp	PP3_mod		PS3_strong	VUS -> LP
p.Asn932Lys	PM2_supp	PP3_mod		PS3_strong	VUS -> LP
p.Arg1305Cys				BS3_mod	VUS -> VUS